U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959082) titled 'Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer' on April 16.
Brief Summary: This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Head and Neck Cancer Squamous Cell Carcinoma
Intervention:
DRUG: VS-101
VS-101
DRUG: Cisplatin
Cisplatin
RADIATION: Radiation
Radiation
Recruitment Status: NOT_YET_RECRUITING
Sponsor: VSPharmTech Co.,Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....